Paul T. Quinlan, General Counsel at Oruka Therapeutics, Inc. (ORKA), sold 10,000 shares at $92.37 ($936K) on 2026-09-21, disclosed to the SEC on 2026-09-21.
Scheduled sale ($936k) by General Counsel under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $92.37 | 2,900 | $268K | 28.6% |
| 2 | $93.32 | 3,832 | $358K | 38.2% |
| 3 | $94.44 | 601 | $57K | 6.1% |
| 4 | $95.31 | 2,667 | $254K | 27.1% |
| Total | $93.64 avg | 10,000 | $936K | 100% |
| Filing → |
| ORKA | SELL | 2026-06-15 | $51K | — | Filing → |
| ORKA | SELL | 2026-03-17 | $30K | — | Filing → |
| CBAY | SELL | 2024-01-16 | $236K | — | Filing → |